Sorrento signs option for all-stock acquisition of Igdrasol run by developers of Abraxane
This article was originally published in Scrip
Executive Summary
San Diego-based Sorrento Therapeutics signed an exclusive option to acquire Igdrasol, a private company in Fountain Valley, California that develops second-generation chemotherapy agents and is run by former Abraxis Bioscience employees involved in the creation of Celgene's blockbuster Abraxane.